Personal information

Other IDs

Scopus Author ID: 16310447300

Activities

Collapse all

Employment (11)

University of Iowa: Iowa City, US

2024-07-01 to present | Professor (Ophthalmology and Visual Sciences)
Employment
Source: Self-asserted source
Elliott Sohn

University of Iowa Hospitals and Clinics: Iowa City, IA, US

2010-08-02 to present | Attending Staff (Ophthalmology and Visual Sciences)
Employment
Source: Self-asserted source
Elliott Sohn

University of Iowa Hospitals and Clinics: Iowa City, IA, US

2016-07-01 to 2024-06-30 | Associate Professor (with tenure) (Department of Ophthalmology and Visual Sciences)
Employment
Source: Self-asserted source
Elliott Sohn

University of Iowa Hospitals and Clinics: Iowa City, IA, US

2010-08-02 to 2016-06-30 | Assistant Professor (Department of Ophthalmology and Visual Sciences)
Employment
Source: Self-asserted source
Elliott Sohn

USC Keck School of Medicine: Los Angeles, CA, US

2009 to 2011 | Adjunct Faculty (Zilkha Neurogenetic Institute)
Employment
Source: Self-asserted source
Elliott Sohn

Childrens Hospital Los Angeles: Los Angeles, CA, US

2009 to 2010 | Clinical Fellow
Employment
Source: Self-asserted source
Elliott Sohn

USC University Hospital: Los Angeles, CA, US

2008 to 2010 | Faculty Fellow Medical Staff
Employment
Source: Self-asserted source
Elliott Sohn

USC Keck School of Medicine: Los Angeles, CA, US

2008 to 2010 | Clinical Instructor (Ophthalmology)
Employment
Source: Self-asserted source
Elliott Sohn

LA County Medical Center: Los Angeles, CA, US

2008 to 2010 | Attending Staff
Employment
Source: Self-asserted source
Elliott Sohn

Hollywood Presbyterian Medical Center: Los Angeles, CA, US

2008 to 2009 | Provisional Staff
Employment
Source: Self-asserted source
Elliott Sohn

National Health Service England: London, England, GB

2007 to 2008 | Medical Staff
Employment
Source: Self-asserted source
Elliott Sohn

Education and qualifications (6)

Doheny Eye Institute/USC: Los Angeles, California, US

2008 to 2010 | Vitreoretinal Surgery Fellowship (Ophthalmology)
Education
Source: Self-asserted source
Elliott Sohn

Moorfields Eye Hospital: London, London, GB

2007 to 2008 | Medical Retina Fellow (Ophthalmology(Sponsor: Alan Bird)
Education
Source: Self-asserted source
Elliott Sohn

University of Washington: Seattle, WA, US

2004 to 2007 | Resident (Ophthalmology)
Education
Source: Self-asserted source
Elliott Sohn

University of Washington: Seattle, WA, US

2003 to 2004 | Internship (Internal Medicine)
Education
Source: Self-asserted source
Elliott Sohn

University of Washington School of Medicine: Seattle, Washington, US

1998 to 2003 | MD
Education
Source: Self-asserted source
Elliott Sohn

Williams College: Williamstown, MA, US

1994 to 1998 | BA
Education
Source: Self-asserted source
Elliott Sohn

Funding (10)

Unraveling the 10q AMD Risk Locus

2016-09 to 2020 | Grant
National Institutes of Health (MD, MD, US)
Part of GRANT_NUMBER:

R01-EY026087
Source: Self-asserted source
Elliott Sohn

Choroidal Disease Mechanisms in AMD

2016-04 to 2021-03 | Grant
National Eye Institute/National Institutes of Health (Bethesda, US)
Part of GRANT_NUMBER:

R01-EY026547-01
Source: Self-asserted source
Elliott Sohn

CRISPR/Cas9-Mediated Correction of Mutations that Cause Inherited Retinal Degenerations

2016-04 to 2019-03 | Grant
National Eye Institute (MD, MD, US)
Part of GRANT_NUMBER:

R01-EY026008-01
Source: Self-asserted source
Elliott Sohn

Capleea Study-Safety and tolerability of intravitreal (IVT) REGN2176-3 in patients with neovascular AMD

2015-06 to 2018-06 | Grant
Regeneron Pharmaceuticals (NY, NY, US)
Part of GRANT_NUMBER:

R2176-3-AMD-1417
Source: Self-asserted source
Elliott Sohn

A long-term follow-up study to evaluate the safety of RetinoStat in patients with age-related macular degeneration

2015-05 to 2025-05 | Grant
Oxford Biomedica (Oxford, GB)
Part of GRANT_NUMBER:

RS1/002/11
Source: Self-asserted source
Elliott Sohn

Elucidating the role of Lp-PLA2 in Streptozotocin-induced diabetic mice

2014-07 to 2015-07 | Grant
GlaxoSmithKline (Brentford, Middlesex, GB)
Part of GRANT_NUMBER:

100039229
Source: Self-asserted source
Elliott Sohn

The GEM Study: A Phase I dose escalation safety study of subretinally injected RetioStat, a lentiviral vector expressing endostatin and angiostatin, in patients with advanced neovascular age-related macualr degeneration

2013-05 to 2015-05 | Grant
Oxford Biomedica (Oxford, GB)
Part of GRANT_NUMBER:

RS1/001/10
Source: Self-asserted source
Elliott Sohn

Acucela Trial

2013-04 to 2016-04 | Grant
Acucela, Inc. (San Francisco, US)
Part of GRANT_NUMBER:

4429-202
Source: Self-asserted source
Elliott Sohn

Safety and efficacy study in submects with Leber Congenital Amaurosis (LCA) using adeno-associated viral vector to deliver the gene for human RPE65 into the retinal pigment epithelium (RPE)

2012-06 to 2027-06 | Grant
Children's Hospital of Philadelphia (PA, PA, US)
Part of GRANT_NUMBER:

AAV2-h-RPE65v2-301
Source: Self-asserted source
Elliott Sohn

Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally, controlled symptoms of schizophrenia treated with antiphychotics followed by a 40-week double-blind, parallel-group, placebo-controlled treatment group

2011-12 to 2015-02 | Grant
Hoffman-LaRoche (Nutley, New Jersey, US)
Part of GRANT_NUMBER:

NN25310
Source: Self-asserted source
Elliott Sohn

Peer review (2 reviews for 2 publications/grants)

Review activity for American journal of ophthalmology. (1)
Review activity for British journal of ophthalmology (1)
How many people are using ORCID?